Expanding the liver donor pool worldwide with hepatitis C infected livers, is it the time?  

作　　者：Mai Hashem Mohammed A Medhat Doaa Abdeltawab Nahed A Makhlouf 

机构地区：[1]Fellow of Tropical Medicine and Gastroenterology,Assiut University Hospital,Assiut 71515,Egypt [2]Department of Tropical Medicine and Gastroenterology,Faculty of Medicine,Assiut University,Assiut 71515,Egypt [3]Department of Tropical Medicine and Gastroenterology,Al-Rajhi Liver Hospital,Assiut University,Assiut 71515,Egypt

出　　处：《World Journal of Transplantation》2024年第2期13-27,共15页世界移植杂志

摘　　要：Liver transplantation(LT)provides a life-saving option for cirrhotic patients with complications and hepatocellular carcinoma.Despite the increasing number of liver transplants performed each year,the number of LT candidates on the waitlist remains unchanged due to an imbalance between donor organ supply and the demand which increases the waitlist time and mortality.Living donor liver transplant had a great role in increasing the donor pool and shortened waitlist time for LT candidates.Nevertheless,further strategies can be implemented to increase the pool of potential donors in deceased donor LT,such as reducing the rate of organ discards.Utilizing hepatitis C virus(HCV)seropositive liver grafts is one of the expanded donor organ criteria.A yearly increase of hundreds of transplants is anticipated as a result of maximizing the utilization of HCV-positive organs for HCV-negative recipients.Direct-acting antiviral therapy's efficacy has revolutionized the treatment of HCV infection and the use of HCV-seropositive donors in transplantation.The American Society of Transplantation advises against performing transplants from HCV-infected liver donors(D+)into HCV-negative recipient(R-)unless under Institutional Review Board-approved study rules and with full informed consent of the knowledge gaps associated with such transplants.Proper selection of patients to be transplanted with HCV-infected grafts and confirming their access to direct-acting antivirals if needed is im-portant.National and international consensuses are needed to regulate this process to ensure the maximum benefit and the least adverse events.

关 键 词：Donor pool Hepatitis C-viremic organs Non-viremic organs Direct acting antivirals Hepatitis C virus treated Liver transplantation 

分 类 号：R699.2[医药卫生—泌尿科学]